News

G2G Wants Your Input to Contribute to New ARPA-H Initiative

The White House Office of Science & Technology Policy (OSTP) is establishing the framework for the Advanced Research Projects Agency-Health (ARPA-H) that was included in President Biden’s FY2022 budget. Modeled after the Defense Advanced Research Projects Agency (DARPA), ARPA-H would tackle bold challenges requiring large-scale, cross-sector coordination, employing a non-traditional and nimble approach to high-risk research. Specifically, under Director Eric Lander, PhD from the Broad Institute and MIT who was sworn in as the first Cabinet level Director of OSTP on June 2, 2021, ARPA-H will advance translational science and drive transformational health innovations that tackle gaps in the system and implement health breakthroughs.

G2G is participating in efforts to contribute input to help shape how ARPA-H will function and we would love to hear your thoughts and questions you would like us to address as we continue our dialogue with the OSTP and ARPA-H leadership.

Click here to provide G2G with your feedback.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or